Who's Running Pfizer's Neurontin Antitrust Defense? Judge Says Company, Counsel "Inverted" Their Roles
This article was originally published in The Pink Sheet Daily
Executive Summary
A magistrate judge says Pfizer has failed to find a witness who knows the basis for the company's denial of off-label marketing of the anti-epileptic; direct purchasers granted class certification.
You may also be interested in...
Pfizer Must Pay Kaiser Cost-Difference Of Cheaper Drugs Under Neurontin Marketing Ruling
Judge Patti Saris finds Pfizer fraudulently marketed its anti-epileptic in violation of California law and orders the company to pay Kaiser $95 million.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.